Suppr超能文献

[手术治疗在难治性腹水治疗中的作用]

[Role of surgical therapy in the treatment of refractory ascites].

作者信息

Pisani Ceretti A, Intra M, Borzio M, Santambrogio R, Opocher E, Ballarini C, Cordovana A, Motta R, Spina G P

机构信息

II Divisione di Chirurgia, Ospedale Fatebenefratelli e Oftalmico, Milano.

出版信息

Minerva Chir. 1997 Nov;52(11):1339-48.

PMID:9489332
Abstract

In 5-10% of cases ascites is not controlled by medical therapy and is defined refractory. These patients may be submitted to one of the four following surgical options: portal-systemic shunt, peritoneo-venous shunt, transjugular intrahepatic portal-systemic shunt, orthotopic liver transplantation. Although the portal-systemic shunt is efficient in clearing ascites, it does not improve the survival, which depends on liver function, and it is complicated by an important incidence of encephalopathy. Since the patients with refractory ascites and good hepatic risk are not usually many, it is possible to understand why derivative surgery has been disappointing with this indication. Although the peritoneo-venous shunt is associated with a significant rate of valve obstruction, it is an easy, effective and not expensive treatment. So, till now, it has been considered the first choice procedure of refractory ascites, if any situations, determinating the onset of postoperative complications, are not present. Recently a new method has been introduced in the therapy of portal hypertension, the transjugular intrahepatic portal-systemic shunt. This is a bloodless portal-systemic derivation and so it has caused great enthusiasm even if the available data are insufficient to give a definitive opinion on its role in management of ascites. Certainly the liver transplantation, which presents the great advantage to treat both the cirrhosis and its complications, seems to be the most rational therapy for these patients. However, at least for this moment, the well-known absence of organ donors makes still actual the palliative surgical measures.

摘要

在5% - 10%的病例中,腹水无法通过药物治疗得到控制,被定义为难治性腹水。这些患者可接受以下四种手术选择之一:门体分流术、腹腔静脉分流术、经颈静脉肝内门体分流术、原位肝移植。尽管门体分流术在清除腹水上有效,但它并不能提高生存率,生存率取决于肝功能,且会并发严重的肝性脑病。由于难治性腹水且肝脏风险良好的患者通常不多,因此可以理解为什么这种适应症的分流手术一直令人失望。尽管腹腔静脉分流术与较高的瓣膜阻塞率相关,但它是一种简单、有效且成本不高的治疗方法。所以,到目前为止,如果不存在任何导致术后并发症的情况,它一直被认为是难治性腹水的首选治疗方法。最近,一种治疗门静脉高压的新方法——经颈静脉肝内门体分流术被引入。这是一种无血的门体分流术,因此即使现有数据不足以对其在腹水治疗中的作用给出明确意见,它还是引起了极大的关注。当然,原位肝移植具有治疗肝硬化及其并发症的巨大优势,似乎是这些患者最合理的治疗方法。然而,至少目前,众所周知的器官供体短缺使得姑息性手术措施仍然具有现实意义。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验